Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

NCT03703375 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03703375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03703375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
November 6, 2018
Completion date
March 30, 2026
Enrollment
93 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, t-cell